Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606901 · ClinicalTrials.gov registry record · Phase 4
Comparison of Time to Extubation Using Sugammadex or Neostigmine
A Phase 4 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT04606901 is a Phase 4 study that has completed, run by Temple University. The registered enrollment target is 58 participants.
The verdict
NCT04606901, a Phase 4 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
Interventions
- DRUG sugammadex
- DRUG neostigmine/glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606901
The ClinicalTrials.gov registry entry for NCT04606901 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sugammadex is the first listed.
NCT04606901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04606901 about?
NCT04606901 is a clinical study titled "Comparison of Time to Extubation Using Sugammadex or Neostigmine". A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
What is the current status of trial NCT04606901?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2021-04-08. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT04606901?
The interventions under investigation include: sugammadex (DRUG), neostigmine/glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT04606901?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.